title: Osteoporosis: what's new and on the horizon.
abstract: In this review, we consider new concepts in the assessment of fracture risk and pharmacologic therapy for osteoporosis. We discuss trabecular bone score, a new imaging technology that adds information that cannot be obtained by only measuring bone mineral density by dual-energy x-ray absorptiometry. We also discuss innovations in antiresorptive, osteoanabolic, and combination therapy; and newer therapeutic classes, including cathepsin K inhibitors and antisclerostin antibodies. We do not cover agents that have not yet been studied in human clinical trials or that are no longer under active investigation.
authors.affiliation: Department of Medicine, Metabolic Bone Diseases Unit, College of Physicians and Surgeons, Columbia University, New York, New York.
authors.forename: Barbara C
authors.initials: BC
authors.lastname: Silva
authors.forename: Aline G
authors.initials: AG
authors.lastname: Costa
authors.forename: Natalie E
authors.initials: NE
authors.lastname: Cusano
authors.forename: John P
authors.initials: JP
authors.lastname: Bilezikian
mesh_terms: D015502:Absorptiometry, Photon / Q000379:methods*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D010024:Osteoporosis / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000209:etiology / Q000517:prevention & control*; D018570:Risk Assessment
chemical_list: D050071:Bone Density Conservation Agents